159 related articles for article (PubMed ID: 35464007)
1. Therapeutic Prospects of Polysaccharides for Ovarian Cancer.
Wang K; Cai M; Sun S; Cheng W; Zhai D; Ni Z; Yu C
Front Nutr; 2022; 9():879111. PubMed ID: 35464007
[TBL] [Abstract][Full Text] [Related]
2. Combination of Niraparib, Cisplatin and Twist Knockdown in Cisplatin-Resistant Ovarian Cancer Cells Potentially Enhances Synthetic Lethality through ER-Stress Mediated Mitochondrial Apoptosis Pathway.
Bahar E; Kim JY; Kim DC; Kim HS; Yoon H
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33920140
[TBL] [Abstract][Full Text] [Related]
3. The Role of Genistein and its Derivatives in Ovarian Cancer: New Perspectives for Molecular Mechanisms and Clinical Applications.
Chaichian S; Nikfar B; Bidgoli SA; Moazzami B
Curr Med Chem; 2023 Oct; ():. PubMed ID: 37921172
[TBL] [Abstract][Full Text] [Related]
4. δ-Tocotrienol sensitizes and re-sensitizes ovarian cancer cells to cisplatin via induction of G1 phase cell cycle arrest and ROS/MAPK-mediated apoptosis.
Fontana F; Marzagalli M; Raimondi M; Zuco V; Zaffaroni N; Limonta P
Cell Prolif; 2021 Nov; 54(11):e13111. PubMed ID: 34520051
[TBL] [Abstract][Full Text] [Related]
5. Niclosamide (NA) overcomes cisplatin resistance in human ovarian cancer.
Huang L; Zhang J; Deng Y; Wang H; Zhao P; Zhao G; Zeng W; Wang Y; Chen C; Wagstaff W; Haydon RC; Reid RR; He TC; Shen L; Luu HH; Zhao L
Genes Dis; 2023 Jul; 10(4):1687-1701. PubMed ID: 37397523
[TBL] [Abstract][Full Text] [Related]
6. Fuzheng Jiedu Decoction Induces Apoptosis and Enhances Cisplatin Efficacy in Ovarian Cancer Cells
Yang H; Li H; Lu S; Shan S; Guo Y
Biomed Res Int; 2022; 2022():5739909. PubMed ID: 35281608
[TBL] [Abstract][Full Text] [Related]
7. Costunolide induces apoptosis in platinum-resistant human ovarian cancer cells by generating reactive oxygen species.
Yang YI; Kim JH; Lee KT; Choi JH
Gynecol Oncol; 2011 Dec; 123(3):588-96. PubMed ID: 21945308
[TBL] [Abstract][Full Text] [Related]
8. The cyclin-dependent kinase inhibitor AT7519 augments cisplatin's efficacy in ovarian cancer via multiple oncogenic signaling pathways.
Wang L; Chen Y; Li H; Xu Q; Liu R
Fundam Clin Pharmacol; 2022 Feb; 36(1):81-88. PubMed ID: 34212421
[TBL] [Abstract][Full Text] [Related]
9. MicroRNAs as the critical regulators of Cisplatin resistance in ovarian cancer cells.
Moghbeli M
J Ovarian Res; 2021 Sep; 14(1):127. PubMed ID: 34593006
[TBL] [Abstract][Full Text] [Related]
10. MiR-1294 confers cisplatin resistance in ovarian Cancer cells by targeting IGF1R.
Zhang Y; Huang S; Guo Y; Li L
Biomed Pharmacother; 2018 Oct; 106():1357-1363. PubMed ID: 30119207
[TBL] [Abstract][Full Text] [Related]
11. Exosome-liposome hybrid nanoparticle codelivery of TP and miR497 conspicuously overcomes chemoresistant ovarian cancer.
Li L; He D; Guo Q; Zhang Z; Ru D; Wang L; Gong K; Liu F; Duan Y; Li H
J Nanobiotechnology; 2022 Jan; 20(1):50. PubMed ID: 35078498
[TBL] [Abstract][Full Text] [Related]
12. DMBT1 suppresses cell proliferation, migration and invasion in ovarian cancer and enhances sensitivity to cisplatin through galectin-3/PI3k/Akt pathway.
Ma N; Zhao Y
Cell Biochem Funct; 2020 Aug; 38(6):801-809. PubMed ID: 32424818
[TBL] [Abstract][Full Text] [Related]
13. Selenium-enriched polysaccharides from Pyracantha fortuneana (Se-PFPs) inhibit the growth and invasive potential of ovarian cancer cells through inhibiting β-catenin signaling.
Sun Q; Dong M; Wang Z; Wang C; Sheng D; Li Z; Huang D; Yuan C
Oncotarget; 2016 May; 7(19):28369-83. PubMed ID: 27058760
[TBL] [Abstract][Full Text] [Related]
14. Plant-Derived Chinese Medicine Monomers on Ovarian Cancer via the Wnt/
Xu JY; Liu FY; Liu SX; Xie LZ; Li J; Ma YT; Han FJ
J Oncol; 2021; 2021():6852867. PubMed ID: 34912456
[TBL] [Abstract][Full Text] [Related]
15. Silencing of miR-1246 Induces Cell Cycle Arrest and Apoptosis in Cisplatin-Resistant Ovarian Cancer Cells by Promoting ZNF23 Transcription.
Cai L; Zhang Q; Du L; Zheng F
Cytogenet Genome Res; 2021; 161(10-11):488-500. PubMed ID: 34923485
[TBL] [Abstract][Full Text] [Related]
16. The anti-tumor effect of OP-B on ovarian cancer in vitro and in vivo, and its mechanism: An investigation using network pharmacology-based analysis.
Yuan S; Xu Y; Yi T; Wang H
J Ethnopharmacol; 2022 Jan; 283():114706. PubMed ID: 34614446
[TBL] [Abstract][Full Text] [Related]
17. Novel Aurora A Kinase Inhibitor Fangchinoline Enhances Cisplatin-DNA Adducts and Cisplatin Therapeutic Efficacy in OVCAR-3 Ovarian Cancer Cells-Derived Xenograft Model.
Winardi D; Chu PY; Chen GY; Wang K; Hsu WY; Hsieh CL; Chen YH; Wu YC; Yang JC
Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163790
[TBL] [Abstract][Full Text] [Related]
18. Double Insurance for OC: miRNA-Mediated Platinum Resistance and Immune Escape.
Zou X; Zhao Y; Liang X; Wang H; Zhu Y; Shao Q
Front Immunol; 2021; 12():641937. PubMed ID: 33868274
[TBL] [Abstract][Full Text] [Related]
19. Astragalus polysaccharides inhibit ovarian cancer cell growth via microRNA-27a/FBXW7 signaling pathway.
Guo Y; Zhang Z; Wang Z; Liu G; Liu Y; Wang H
Biosci Rep; 2020 Mar; 40(3):. PubMed ID: 32159214
[TBL] [Abstract][Full Text] [Related]
20. Xiaoaiping combined with cisplatin can inhibit proliferation and invasion and induce cell cycle arrest and apoptosis in human ovarian cancer cell lines.
Zheng AW; Chen YQ; Fang J; Zhang YL; Jia DD
Biomed Pharmacother; 2017 May; 89():1172-1177. PubMed ID: 28320083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
